MYD88 and diffuse large B-cell lymphoma: This retrospective study assessed the efficacy and safety of the ZR-CHOP regimen in MYD88-mutated DLBCL patients, focusing on whether adding zanubrutinib could improve outcomes in this high-risk group known for poor prognosis.